Summary: A randomized, double-blind, placebo-controlled clinical trial found that switching from combustible cigarettes to a pod-based salt-nicotine electronic cigarette substantially increased short-term smoking cessation and reduced exposure to several tobacco-related toxicants.
In the trial, daily smokers assigned to a 5% nicotine pod-based e-cigarette were about three times more likely to quit smoking within six weeks compared with those given an identical-looking, nicotine-free placebo device. The study offers practical evidence for public health officials and clinicians considering non-combustible alternatives for people who have not been able to quit with standard pharmacotherapies.
Key Facts
- Three-fold higher quit rate: By six weeks, 36.5% of participants using the 5% nicotine device reported complete cigarette abstinence versus 11.5% in the zero-nicotine group; this difference persisted at a 10-week follow-up.
- Reduced carcinogen exposure: Both groups showed declines in tobacco-related toxicants, including NNAL (a tobacco-specific lung carcinogen derived from the tobacco leaf). The 5% nicotine group experienced the largest reductions in several biomarkers.
- Efficient nicotine delivery: Modern pod-based devices use a nicotine salt formulation that delivers nicotine more smoothly and efficiently than older e-cigarette designs, better suppressing withdrawal and cravings and supporting behavioral switching away from cigarettes.
- U.S. randomized placebo-controlled data: This trial is reported to be the first U.S.-based randomized, double-blind, placebo-controlled study directly testing the chemical and behavioral effects of switching completely from combustible cigarettes to pod-based salt-nicotine e-cigarettes.
- Harm reduction principle: The study reinforces the public health distinction between nicotine (the addictive agent) and the harmful byproducts produced by burning tobacco, which are the main contributors to smoking-related cancers and cardiovascular disease.
Source: Penn State
Cigarette smoking remains the leading preventable cause of death in the United States, even as national smoking prevalence has declined. Emerging evidence has suggested that e-cigarettes can reduce exposure to many toxic combustion byproducts and help some people quit smoking, but product designs and formulations have changed rapidly. This trial focused on pod-based salt-nicotine devices, a widely used modern category of e-cigarette.
Published in JAMA Network Open, the trial enrolled 104 adults who smoked more than four cigarettes per day and expressed interest in switching completely to an e-cigarette. Participants were randomized 1:1 to receive either a 5% nicotine pod-based device or an identical 0% nicotine device as a placebo. Neither participants nor study staff knew device assignments.
Participants were instructed to stop smoking combustible cigarettes and use the assigned e-cigarette for six weeks, with a follow-up at 10 weeks. The placebo device provided the sensory aspects of vaping—vapor production and hand-to-mouth motion—without delivering nicotine, allowing researchers to isolate the behavioral and pharmacologic effects of nicotine delivery.
Researchers measured urine and breath biomarkers at baseline, three weeks, and six weeks to track exposure to tobacco-specific toxicants. The primary biomarker was NNAL, a metabolite that indicates exposure to a potent, tobacco-derived lung carcinogen. Secondary measures included exhaled carbon monoxide (CO), cotinine, cigarettes per day (CPD), and volatile organic compound metabolites tied to respiratory and cardiovascular harm.
At six weeks, 69 participants completed the study (35 in the 5% nicotine group and 34 in the 0% group). Both groups showed decreases in several toxicant biomarkers compared with baseline, indicating reduced exposure when participants used e-cigarettes instead of traditional cigarettes. The reductions were more pronounced in the 5% nicotine group, although differences in some measures approached but did not reach statistical significance after adjusting for baseline variables.
Importantly, the 5% nicotine group had significantly higher cotinine levels—consistent with nicotine delivery from the device—and a substantially higher verified quit rate. The authors note that better nicotine delivery likely reduced withdrawal and cravings, enabling more participants to switch away from combustible cigarettes. Biomarkers of specific toxins, including markers of exposure to acrylonitrile and acrolein, were also lower in the nicotine group.
Lead author Jessica Yingst, associate professor of public health sciences, emphasized that while nicotine is addictive, the major harms of smoking arise from combustion byproducts. For smokers unable to quit with approved medications, a pod-based nicotine e-cigarette that delivers nicotine effectively may serve as a pragmatic harm-reduction tool, lowering exposure to major tobacco toxicants while increasing the likelihood of quitting cigarettes.
Key Questions Answered
A: The concept is harm reduction. Although ideal public health outcomes involve complete nicotine and tobacco cessation, many smokers struggle to quit. Removing combustion greatly reduces exposure to the most dangerous chemicals produced by burning tobacco. This trial shows that switching to a pod-based nicotine e-cigarette lowers exposure to several known carcinogens and toxicants, offering a meaningful reduction in risk compared with continuing to smoke.
A: The zero-nicotine device acted as a placebo: it reproduced the behavioral and sensory aspects of smoking but provided no nicotine replacement. Without nicotine to relieve withdrawal and cravings, most participants using the placebo device found it difficult to stop smoking completely.
A: Pod-based devices commonly use a nicotine salt formulation that increases nicotine bioavailability and smooths delivery, producing a satisfaction profile closer to that of cigarettes. That stronger, faster nicotine delivery better suppresses cravings and makes sustained switching from combustible cigarettes more achievable for many smokers.
Editorial Notes
- This article was edited by a Neuroscience News editor.
- The journal paper was reviewed in full by editorial staff.
- Additional context was provided by the editorial team to clarify implications for public health.
About this research
Author: Christine Yu
Source: Penn State
Contact: Christine Yu – Penn State
Image credit: Neuroscience News
Original research: Open access. “Toxicant Exposures After Switching From Cigarettes to a Pod-Based Electronic Cigarette” by Jessica M. Yingst et al., published in JAMA Network Open. DOI: 10.1001/jamanetworkopen.2026.13292
Trial registration: ClinicalTrials.gov Identifier: NCT03625986
Abstract (condensed)
Importance: Pod-based nicotine salt e-cigarettes are increasingly common, yet evidence is needed on how switching from combustible cigarettes affects toxicant exposure and smoking behavior.
Objective: To assess short-term changes in toxicant biomarkers and smoking cessation after switching from cigarettes to a pod-based 5% nicotine e-cigarette versus a 0% nicotine e-cigarette.
Design and participants: Double-blind, randomized, placebo-controlled trial conducted at a single academic center in Pennsylvania. Adults smoking >4 cigarettes per day who wanted to switch to an e-cigarette were enrolled and randomized 1:1 to 5% or 0% nicotine devices, with assessments at baseline, three weeks, six weeks, and a 10-week follow-up.
Main outcomes: Primary outcome was urine NNAL concentration at six weeks. Secondary outcomes included exhaled CO, cotinine, cigarettes per day, CO-verified abstinence, and volatile organic compound biomarkers.
Results: Of 104 randomized participants, the 5% nicotine group showed a significantly higher cigarette abstinence rate at six weeks (36.5% vs 11.5%). Both groups reduced toxicant exposure from baseline, with larger reductions in several biomarkers among those using the 5% nicotine device. Cotinine levels were higher in the nicotine group, consistent with effective nicotine delivery.
Conclusions: Among adults who smoke, switching completely to a pod-based 5% nicotine e-cigarette versus a 0% nicotine device was associated with reduced exposure to some cigarette-related toxicants and a higher rate of smoking cessation. E-cigarettes that deliver nicotine at levels similar to cigarettes may play a role in reducing harms from combustible tobacco for smokers who cannot quit with conventional therapies.